1.Optimal Management of Heart Failure with Preserve Ejection Fraction.
Korean Journal of Medicine 2015;88(2):135-141
More than 50% of patients who are diagnosed with heart failure have preserved ejection fraction (HFpEF), and they have an equally poor prognosis when compared to patients with heart failure with reduced ejection fraction (HFrEF). However, a comprehensive understanding and awareness of heart failure with preserved ejection fraction is still limited and there are currently no optimized treatments to improve morbidity and mortality in these patients. This review summarizes the differences in the epidemiology, pathophysiology, diagnosis, and prognosis between HFpEF and HFrEF. We also review current management strategies of HFpEF patients according to evidence-based treatment guidelines.
Diagnosis
;
Epidemiology
;
Heart Failure*
;
Heart Failure, Diastolic
;
Humans
;
Mortality
;
Prognosis
3.KSHF Guidelines for the Management of Acute Heart Failure: Part I. Definition, Epidemiology and Diagnosis of Acute Heart Failure
Ju Hee LEE ; Min Seok KIM ; Eung Ju KIM ; Dae Gyun PARK ; Hyun Jai CHO ; Byung Su YOO ; Seok Min KANG ; Dong Ju CHOI
Korean Circulation Journal 2019;49(1):1-21
The prevalence of heart failure (HF) is on the rise due to the aging of society. Furthermore, the continuous progress and widespread adoption of screening and diagnostic strategies have led to an increase in the detection rate of HF, effectively increasing the number of patients requiring monitoring and treatment. Because HF is associated with substantial rates of mortality and morbidity, as well as high socioeconomic burden, there is an increasing need for developing specific guidelines for HF management. The Korean guidelines for the diagnosis and management of chronic HF were introduced in March 2016. However, chronic and acute heart failure (AHF) represent distinct disease entities. Here, we introduce the Korean guidelines for the management of AHF with reduced or preserved ejection fraction. Part I of this guideline covers the definition, epidemiology, and diagnosis of AHF.
Aging
;
Diagnosis
;
Epidemiology
;
Heart Failure
;
Heart
;
Humans
;
Mass Screening
;
Mortality
;
Prevalence
4.Clinical and Echocardiographic Findings of Newly Diagnosed Acute Decompensated Heart Failure in Elderly Patients.
Jeonggeun MOON ; Seok Min KANG ; In Jeong CHO ; Jaewon OH ; Jaemin SHIM ; Sang Hak LEE ; Yangsoo JANG ; Namsik CHUNG
Yonsei Medical Journal 2011;52(1):33-38
PURPOSE: Elderly patients (pts) (EPs; > or = 65 years old) with newly diagnosed-acute decompensated heart failure (ND-ADHF) have not yet been studied. The aim of the present study was to investigate clinical characteristics, including echocardiographic findings and prognosis, for EPs with ND-ADHF and to compare those with non-elderly pts (NEPs). MATERIALS AND METHODS: We retrospectively investigated 256 pts (144 males, 63.0 +/- 14.8 years old) who were admitted to our hospital between January 2005 and March 2009 with ND-ADHF. Clinical characteristics and echocardiographic parameters were analyzed in EPs (n = 135, 58 males) and NEPs (n = 121, 86 males). RESULTS: In intergroup comparison, female gender, diabetes mellitus, previous stroke and hypertension were more common in EPs. Body mass index (22.3 +/- 4.5 vs. 24.0 +/- 4.4 kg/m2), estimated glomerular filtration rate (54.8 +/- 24.3 vs. 69.2 +/- 30.7 mL/min/m2), C-reactive protein (28.5 +/- 46.9 vs. 7.6 +/- 11.6 mg/dL), hemoglobin (12.3 +/- 2.1 vs. 13.6 +/- 2.3 g/dL) and N-terminal pro-brain natriuretic peptide level (10,538.2 +/- 10,942.3 vs. 6,771.0 +/- 8,964.7 pg/mL) were significantly different (p < 0.05 for all). Early mitral inflow velocity to early diastolic mitral annular velocity (E/E') was significantly higher in EPs than in NEPs (21.2 +/- 9.4 vs. 18.0 +/- 8.9, p < 0.05). During follow-up (44.7 +/- 14.5 months), there were no significant differences in in-hospital mortality, re-hospitalization and cardiovascular mortality between EPs and NEPs (p = NS for all). CONCLUSION: EPs with ND-ADHF have different clinical characteristics and higher LV filling pressure when compared with NEPs. However, the clinical outcomes for NEPs with ND-ADHF are not necessarily more favorable than those for EPs.
Aged
;
Echocardiography/*methods
;
Female
;
Heart Failure/*diagnosis/*epidemiology
;
Humans
;
Male
;
Middle Aged
;
Retrospective Studies
5.Clinical epidemiologic investigation on Chinese medicine syndrome laws in patients with chronic heart failure.
Xu ZOU ; Guang-ming PAN ; Xiao-gang SHENG
Chinese Journal of Integrated Traditional and Western Medicine 2011;31(7):903-908
OBJECTIVETo study the distribution laws of Chinese medicine syndromes in patients with chronic heart failure (CHF) by clinical epidemiologic investigation.
METHODS512 CHF patients were studied, including 168 items of symptoms and 48 items of tongue and pulse pictures. A database of Chinese medicine syndromes was established, and 9 disease nature elements and 5 disease location elements were extracted. Frequency analysis was performed on all symptoms, tongue and pulse pictures. The variables with frequency constituent ratio less than 10.0% were deleted. Then the features of clinical epidemiology, syndrome patterns, syndrome elements, main symptoms, as well as tongue and pulse pictures were analyzed.
RESULTS(1) The disease nature elements of CHF covered qi deficiency, yin deficiency, and yang deficiency (categorized as the essential deficiency), as well as blood stasis, turbid phlegm, and the retained fluid (categorized to the superficiality excess). Among them, frequencies of qi deficiency and blood stasis (both more than 85.0%) were the highest. The disease location elements of CHF were ordered in frequency as Xin (97.9%), Pi (88.1%), followed by Shen (43.0%), Fei (30. 1%), and Gan (7.0%). (2) In the distribution of syndrome patterns in CHF patients, qi deficiency phlegm-stasis syndrome was the most (59.2%), followed by qi-yin deficiency with phlegm-stasis intermingle syndrome (20.3%), Xin-yang decline with phlegm-stasis obstruction syndrome (7.0%), and yang-deficiency with water overflowing syndrome (5.5%). (3) Patients with heart function grade II, III, and IV mainly manifested as qi-deficiency with phlegm-stasis syndrome. Besides, qi-yin deficiency with phlegm-stasis intermingle syndrome could be often seen in those with grade III. And Xin-yang decline with phlegm-stasis obstruction syndrome and yang-deficiency with water overflowing syndrome could often be seen in those with grade IV.
CONCLUSIONSThe pathogenesis of CHF is essential deficiency and superficiality excess. The essentiality consists of qi deficiency, yin deficiency, and yang deficiency, and the superficiality consists of blood stasis, turbid phlegm, and retained fluid. The disease was located at the five zang-organs, mainly dominated at Xin and Pi, and associated with Fei, Shen, and Gan. Qi deficiency phlegm-stasis syndrome was dominated in Chinese medicine syndrome patterns. Along with the aggravation of CHF, Chinese medicine syndrome pattern shows certain development laws.
Adolescent ; Adult ; Aged ; Chronic Disease ; Female ; Heart Failure ; diagnosis ; epidemiology ; Humans ; Medicine, Chinese Traditional ; Middle Aged ; Yang Deficiency ; diagnosis ; epidemiology ; Yin Deficiency ; diagnosis ; epidemiology ; Young Adult
6.Review of Epidemiology, Diagnosis, and Treatment of Osteosarcopenia in Korea
Journal of Bone Metabolism 2018;25(1):1-7
Sarcopenia was listed in the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) as M62.84, on October 1, 2016. Sarcopenia is primarily associated with metabolic diseases, such as diabetes, obesity, and cachexia, as well as chronic renal failure, congestive heart failure, and chronic obstructive pulmonary disease. Sarcopenia is also significantly associated with osteoporosis in elderly populations and the combined disease is defined as osteosarcopenia. Several studies have confirmed that sarcopenia and osteoporosis (osteosarcopenia) share common risk factors and biological pathways. Osteosarcopenia is associated with significant physical disability, representing a significant threat to the loss of independence in later life. However, the pathophysiology and diagnosis of osteosarcopenia are not fully defined. Additionally, pharmacologic and hormonal treatments for sarcopenia are undergoing clinical trials. This review summarizes the epidemiology, pathophysiology, diagnosis, and treatment of osteosarcopenia, and includes Korean data.
Aged
;
Cachexia
;
Diagnosis
;
Epidemiology
;
Heart Failure
;
Humans
;
International Classification of Diseases
;
Kidney Failure, Chronic
;
Korea
;
Metabolic Diseases
;
Obesity
;
Osteoporosis
;
Pulmonary Disease, Chronic Obstructive
;
Risk Factors
;
Sarcopenia
7.Fifteen-year evolving trends of etiology and prognosis in hospitalized patients with heart failure.
Zhi-yong PEI ; Yu-sheng ZHAO ; Jia-yue LI ; Qiao XUE ; Lei GAO ; Shi-wen WANG
Chinese Journal of Cardiology 2011;39(5):434-439
OBJECTIVETo investigate the etiological and prognostic changes of hospitalized patients with chronic heart failure.
METHODSThis retrospective study analyzed 7319 hospitalized patients (male 62.07%) with validated primary discharge diagnosis of chronic heart failure in Chinese PLA General Hospital in Beijing from January 1, 1993 to December 31, 2007. Etiological characteristics, comorbidities and 30-day hospitalized mortality in the following three periods: 1993 - 1997 (n = 1623), 1998 - 2002 (n = 2444), and 2003 - 2007 (n = 3252) were compared.
RESULTS(1) The patient age increased [(56.0 ± 17.5) years, (57.8 ± 17.6) years and (62.7 ± 15.5) years, P < 0.01] and hospital stay time decreased [(31.3 ± 17.4) days, (22.7 ± 14.1) days and (20.1 ± 15.2) days, P < 0.01] from 1993 to 2007. (2) The common causes of heart failure were coronary heart disease, hypertension, rheumatic valvular heart disease and diabetes mellitus. From 1993 - 1998 to 2003 - 2007, the proportion of patients with coronary heart disease, hypertension and diabetes mellitus rose from 37.2%, 23.3% and 12.3% to 46.8%, 46.7% and 21.1%, respectively (all P < 0.05). Meanwhile the proportion of patients with rheumatic valvular heart disease fell from 35.2% to 16.6% (P < 0.05). (3) The main etiologies and comorbidities were atrial fibrillation, myocardial infarction, pneumonia, chronic obstructive pulmonary disease and renal failure. From 1993 - 1998 to 2003 - 2007, atrial fibrillation was the most common cause of heart failure, and the rate of myocardial infarction, pneumonia and renal failure rose from 11.0%, 8.9% and 5.2% to 14.7%, 14.5% and 9.1%, respectively (all P < 0.05) and the rate of COPD fell from 12.9% to 8.4% (P < 0.05). (4) The 30-day hospitalized mortalities in the three periods were 7.0%, 4.5% and 5.1%, respectively, and the mortalities in the 1998 - 2002 and 2003 - 2007 periods were lower than those of in the 1993 - 1998 period (all P < 0.05). The mortality related to coronary heart disease decreased significantly from 1993 to 2007 (9.3%, 5.0% and 3.8% in the three periods, respectively, P < 0.05).
CONCLUSIONSIt is demonstrated that the primary diseases causing heart failure were coronary heart disease, hypertension, diabetes mellitus and rheumatic valvular heart disease, and the former three diseases exhibited a upward trend and the later one exhibited a downward trend. Moreover, the proportion of comorbidities in patients with heart failure increased over the study period. The 30-day hospital mortality exhibited a downward trend and decreased significantly in patients with coronary heart disease or myocardial infarction.
Adolescent ; Adult ; Aged ; Aged, 80 and over ; Chronic Disease ; Female ; Heart Failure ; diagnosis ; epidemiology ; mortality ; Humans ; Male ; Middle Aged ; Prognosis ; Retrospective Studies ; Young Adult
9.Association of Congestive Heart Failure and Death with Ankylosing Spondylitis : A Nationwide Longitudinal Cohort Study in Korea
Ki Hwan BAE ; Je Beom HONG ; Yoon Jin CHOI ; Jin Hyung JUNG ; In Bo HAN ; Jung Min CHOI ; Seil SOHN
Journal of Korean Neurosurgical Society 2019;62(2):217-224
OBJECTIVE: We attempted to discover that Ankylosing spondylitis (AS) has a comprehensive relationship with congestive heart failure and death.METHODS: We used a nationwide database managed by the Korean National Health Insurance Service from 2010 to 2014. Twelve thousand nine hundred eighty-eight patients with a diagnosis of AS and 64940 age- and sex- stratified matching subjects without AS were enrolled in the AS and control groups. Incidence probabilities of 6 years congestive heart failure and death in each group were calculated. The Cox proportional hazard regression analysis was used to estimate the hazard ratio. We divided the AS and control groups into subgroups according to sex, age, income, and comorbidities.RESULTS: During the follow-up period, 102 patients (0.79%) in the AS group and 201 patients (0.32%) in the control group developed congestive heart failure (p < ;0.0001). In addition, 211 (1.62%) subjects in the AS group died during the follow-up period compared to 639 (0.98%) subjects in the control group (p < ;0.0001). The adjusted hazard ratio of congestive heart failure and death in the AS group was 2.28 (95% confidence interval [CI], 1.80–2.89) and 1.66 (95% CI, 1.42–1.95), respectively. The hazard ratios of congestive heart failure and death were significantly increased in all of the subgroups.CONCLUSION: The incidence rates of congestive heart failure and death were increased in AS patients.
Cardiovascular Diseases
;
Cohort Studies
;
Comorbidity
;
Diagnosis
;
Epidemiology
;
Estrogens, Conjugated (USP)
;
Follow-Up Studies
;
Heart Failure
;
Humans
;
Incidence
;
Korea
;
National Health Programs
;
Spondylitis, Ankylosing
10.Cardiovascular Events of Electrical Cardioversion Under Optimal Anticoagulation in Atrial Fibrillation: The Multicenter Analysis.
Dong Geum SHIN ; Iksung CHO ; Briain O HARTAIGH ; Hee Sun MUN ; Hye Young LEE ; Eui Seock HWANG ; Jin Kyu PARK ; Jae Sun UHM ; Hui Nam PAK ; Moon Hyoung LEE ; Boyoung JOUNG
Yonsei Medical Journal 2015;56(6):1552-1558
PURPOSE: Electric cardioversion has been successfully used in terminating symptomatic atrial fibrillation (AF). Nevertheless, largescale study about the acute cardiovascular events following electrical cardioversion of AF is lacking. This study was performed to evaluate the incidence, risk factors, and clinical consequences of acute cardiovascular events following electrical cardioversion of AF. MATERIALS AND METHODS: The study enrolled 1100 AF patients (mean age 60+/-11 years) who received cardioversion at four tertiary hospitals. Hospitalizations for stroke/transient ischemic attack, major bleedings, and arrhythmic events during 30 days post electric cardioversion were assessed. RESULTS: The mean duration of anticoagulation before cardioversion was 95.8+/-51.6 days. The mean International Normalized Ratio at the time of cardioversion was 2.4+/-0.9. The antiarrhythmic drugs at the time of cardioversion were class I (45%), amiodarone (40%), beta-blocker (53%), calcium-channel blocker (21%), and other medication (11%). The success rate of terminating AF via cardioversion was 87% (n=947). Following cardioversion, 5 strokes and 5 major bleedings occurred. The history of stroke/transient ischemic attack (OR 6.23, 95% CI 1.69-22.90) and heart failure (OR 6.40, 95% CI 1.77-23.14) were among predictors of thromboembolic or bleeding events. Eight patients were hospitalized for bradyarrhythmia. These patients were more likely to have had a lower heart rate prior to the procedure (p=0.045). Consequently, 3 of these patients were implanted with a permanent pacemaker. CONCLUSION: Cardioversion appears as a safe procedure with a reasonably acceptable cardiovascular event rate. However, to prevent the cardiovascular events, several risk factors should be considered before cardioversion.
Aged
;
Amiodarone/therapeutic use
;
Anti-Arrhythmia Agents/therapeutic use
;
Atrial Fibrillation/*complications/epidemiology/*therapy
;
Bradycardia/epidemiology/etiology
;
Cardiovascular Diseases/epidemiology/*etiology
;
Electric Countershock/*methods
;
Female
;
Heart Failure/epidemiology/etiology
;
Humans
;
Incidence
;
Male
;
Middle Aged
;
Risk Factors
;
Stroke/diagnosis/epidemiology/*etiology
;
Treatment Outcome